February 27, 2021 – February 27, 2022
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and NORTH AMERICAN ROBOTIC UROLOGY SYMPOSIUM (NARUS). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this live activity for a maximum of 3.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Amedco LLC designates this enduring material for a maximum of 3.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives – After Attending This Program You Should Be Able To
- Discuss tips and tricks for successful robotic prostatectomy in the immediate year after training..
- Discuss ideal case selection and technical choices for initial cases of robotic partial nephrectomy.
- Describe how to build a reconstructive urology robotics program.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed in the agenda. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.
|John||Davis||Intuitive Surgical: Speakers Bureau, Janssen: Research Grant Overall Principal Investigator, Medtronic:Consultant|
|Jennifer||Linehan||Urogen: Consultant, Intuitive Surgical: Consultant|